Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin

Inclusion Criteria: 1. Aged between 19 and 75 years 2. Presence of atherosclerotic cardiovascular disease Coronary artery disease * History of acute coronary syndrome * Stable or unstable angina * History of coronary revascularization Stroke or TIA Peripheral arterial disease, history of peripheral arterial revascularization 3. Patients who have been taking lipid-lowering agents (statin or ezetimibe) for ≥4 weeks at the time of randomization 4. Patients who gave informed consent Exclusion Criteria: 1. Patients who have used lipid-lowering agents other than statin or ezetimibe within the last 3 months 2. A serum triglyceride on fasting \>400 mg/dL 3. A history of muscular symptoms or rhabdomyolysis due to the use of statin 4. Hypersensitivity to rosuvastatin or ezetimibe 5. Labeled contraindications to rosuvastatin or rosuvastatin Severe renal impairment (CrCl \<30 mL/min by Cockcroft-Gault formula or estimated GFR \<30 mL/min / 1.73 m2 by MDRD equation) ALT, AST ≥3 × ULN or active liver disease CPK ≥3 × ULN 6. Enrollment of other clinical trials within 30 days 7. Any other issues that the treating physician assumes ineligible for participation in the trial